SocialPicks Sentiment:
** v.s.
other stocks
|
This Quarter's Sentiment:
|
|
|
ACOR Analysis & Videos »
ACOR: Bull or Bear?
FDA Calendar Updates: ACOR, HGSI, RPRX, Pharming
ACOR
|
|
|
-4.63%
in
129 days
<> Below is a summary of updates to the <font> BioMedReports.com FDA Calendar </font> , which includes a database of over 200 entries. The calendar was originally created by Mike Havrilla to track companies with pending new drug, biological agent, or medical device new product decisions at the FDA. With the launch of <font> BioMedReports.com </font> , the FDA Calendar has expanded to include the following categories: pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), pending complete response letter (CRL) re-submissions to the FDA, and pending late-st...
|
FDA, Clinical Trial Calendar Updates: Acorda, Alkermes, GTx
ACOR
|
|
|
+11.82%
in
69 days
(closed on 07/01/09)
<> The FDA Calendar includes companies with pending new drug, biological agent, or medical device new product decisions at the FDA sorted by their PDUFA decision deadline dates while the Clinical Trial Calendar encompasses pending clinical trial results (with a focus on late-stage, Phase 3 trials), pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), and pending re-submissions to the FDA for complete r...
|
Bullish on ACOR ...
ACOR
|
|
|
+12.25%
in
219 days
Acorda Therapeutics, Inc., a biopharmaceutical company, engages in the identification, development, and commercialization of various therapies for the improvement of neurological functions in people with multiple sclerosis (MS), spinal cord injury, and other disorders of the central nervous system in the United States. It markets Zanaflex Capsules and Zanaflex tablets, a short-acting drug indicated for the management of spasticity. The companyÂ’s lead product candidate is Fampridine-SR, which completed two positive Phase III clinical trials for the improvement of walking ability in patients...
|
FDA, Clinical Trial Calendar Updates: Weight Loss, Diabetes, and More
ACOR
|
|
|
+8.21%
in
22 days
(closed on 04/23/09)
<> The FDA Calendar includes companies with pending new drug, biological agent, or medical device new product decisions at the FDA sorted by their PDUFA deadline dates. The entries are updated on a daily basis as new information becomes available with a total of 110 entries through 4/1/09. The FDA Calendar includes the following information: company name, ticker, decision d...
|
FDA Calendar: New Entries, One-Week Outlook
ACOR
|
|
|
-15.22%
in
54 days
(closed on 04/01/09)
FDA Calendar: New Entries, One-Week Outlook The table at my website link below includes 84 pending FDA new product decision dates. Click here for a link to my previous calendars and here for 16 extreme FDA trades of companies with market caps below $150M with pending decisions. New Entries on the FDA Calendar: <> 1.) Acorda Therapeutics (ACOR): ACOR filed a NDA for Fampridine-SR Oral Tablet to improve the walking ability of people with multiple scleros...
|
20 Emerging Healthcare Stocks to Watch in '09
ACOR
|
|
|
+5.08%
in
27 days
(closed on 02/06/09)
<> As a follow-up to my most recent article on the buyout binge among bio-pharma and diagnostic companies, below is a basket of 20 stocks (listed randomly) to consider from the ETF Innovators Indexes of 250 companies which represent a mix of pending catalysts in the form of clinical trials or FDA decisions, innovative patent portfolios or drug discovery technology platforms, promising compounds in clinical development, and marketed therapeutic or diagnostic products. Click on any of the company names for links to all of my prev...
|
People Bullish on ACOR
People Bearish on ACOR
|
ROCK-STAR INVESTORS
|
|
POPULAR STOCKS
|
|
TODAY'S HEADLINES
|
|
TODAY'S TOP PICKS
|
|
|
| StreetInsider.com on ACOR |
More Resources
|
ACOR
About Acorda Therapeutics Inc.
- Answers.com
